Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,951 total articles
Journey Medical's Q2 narrative and commercial update show Emrosi gaining prescription traction despite reimbursement timing noise. At a $192M market cap, improving script flow, falling short interest and bullish technicals create a favorable risk/reward for a mid-term long trade. This idea includes a clear entry at $6.81, a $9.25 target and a $5.25…
LightPath Technologies is increasingly relevant to Western defense and commercial optics supply chains. The company's infrared and thermal optics wins, low leverage, and recently strengthened balance sheet set up a tactical long. We lay out an actionable swing trade with clear entry, target and stop, plus the catalysts and risks that will move the …
Alphabet looks like a classic compounding machine: dominant cash-generating core, an expanding AI moat, and a long-term buyer in Berkshire Hathaway reinforcing the narrative. The valuation and balance sheet give room for patient, structured exposure. This trade idea lays out an actionable plan with entry, stop, and target and explains why the risk/…
Genesco is showing the kind of operating resilience and cash generation that justifies upgrading the stock. Revenue growth at the Journeys division, a clean balance sheet, and low EV/EBITDA and price-to-book multiples give a favorable risk-reward. This trade plan targets a move toward the 52-week high while keeping a disciplined stop.
Rivian's early R2 sales and Q2 margin improvement give the company a clearer path to profitability. With a market cap near $22.8B, improving software and services margins, and meaningful liquidity commitments, this trade favors a long on a measured pullback. Entry at $15.00, stop at $13.50, target at $22.00 over a mid-term (45 trading days) horizon…
Blue Owl (OWL) looks set to extend a multi-week rebound. The alternative asset manager generates meaningful free cash flow, supports a high distribution yield, and has seen short interest ease — a combination that can fuel a mid-term rally. Trade plan: enter at $11.78, target $14.72, stop $10.20. Horizon: mid term (45 trading days).
Travere Therapeutics has run hard from its 52-week low, but its $6.2B market cap and $6.5B enterprise value still leave room for gains if its rare-disease franchise and pipeline continue to convert. Momentum is healthy, free cash flow is positive, and short interest plus activist/legal noise create both downside risk and upside fuel. I outline an a…
Baidu trades at $92.37 with a $37.3B market cap and oversold momentum. The planned IPO of Kunlunxin - Baidu's AI chip and model arm - could force the market to separately value Baidu's high-growth AI franchise versus its legacy search and iQiyi segments. This trade targets a mid-term re-rating on positive IPO reception, product wins, or acceleratin…
Marvell has been swept up in AI infrastructure enthusiasm. The stock is richly valued on thin margin of error: market cap near $205B, trailing P/E in the 70s and FCF yield below 1%. This trade idea proposes a tactical short to fade an overstretched move while offering clear entry, stop and target levels with a mid-term horizon.
Nu Holdings remains one of the highest-conviction growth stories in Latin American fintech. Recent results show 50% revenue growth, a profitable earnings inflection and accelerating monetization per user. With Mexico now open and strong early traction in Colombia, the stock looks well positioned for further multiple expansion. This trade idea lays …
Array Technologies is at an inflection: a new 60-degree DuraTrack variant and solid free cash flow position give the company room to win larger, weather-hardened utility projects in 2027. At a sub-$800M market cap and FCF of $134.7M, the risk/reward looks favorable for a long trade into mid-2027, provided developers lean into hail-resistant tracker…
Marvell's stock is pricing in a transformational customer win. Valuation still looks rich on traditional metrics, but immediate revenue and scale levers — plus a clean balance sheet and bullish technicals — create a favorable risk/reward for a mid-term swing trade. Entry, stop and targets provided.
Enbridge (ENB) offers a 5.4%+ yield, a CA$41 billion secured capital backlog through 2033 and a cash-flow profile that's largely protected by regulated and contract-backed businesses. The stock is trading below several moving averages with RSI ~30, presenting a mid-term buying opportunity. This trade idea lays out an actionable entry, stop and targ…
Tesla shares are down materially from last year's highs, but several underappreciated operational developments and compressed expectations create a defined-risk entry. This trade targets a rebound into the low $400s over the next 45 trading days, with a stop below key technical support and clear exit criteria if robotaxi delays or margin deteriorat…
Carl Zeiss Meditec (CZMWY) has bounced off its March low and technicals now show sustained bullish momentum. With a $3.36B market cap, improving moving averages, and tailwinds in ophthalmics and advanced optics, this trade aims to capture a re-acceleration over the next 45 trading days. Entry, stop and target are defined with a clearly articulated …
AMD's Helios platform rollout and accelerating data-center demand are translating into rapid earnings leverage. With revenue up roughly 50% year-over-year in the last quarter and free cash flow of $8.4B, the company can sustain R&D and capacity growth. Valuation is rich on headline P/E, but execution and margin expansion should drive EPS growth tha…
Merck rallied more than 14% today following reports of a positive cancer vaccine readout in collaboration with Moderna. The move leaves the stock extended but supported by strong free cash flow ($16.06B), a $369B market cap and an attractive dividend yield (~2.49%). We outline a mid-term trade plan to buy a breakout, set a protective stop, and targ…
Rocket Lab's recent $397 million Space Force award changes the investment calculus. The deal, plus a $2.36 billion backlog and visible path to larger, recurring government work, reduces execution risk on top-line visibility while Neutron remains the key operational trigger. Valuation is still demanding, so this is a tactical long with defined stops…
Meta's shares are trading near the recent low after litigation headlines. The company still generates strong free cash flow ($40.98B), posts healthy returns (ROE ~26%), and trades at a ~20x P/E and ~13x EV/EBITDA. This trade idea outlines a mid-term long with a clear entry, stop, and target, while laying out the catalysts and risks that matter.
Jade Biosciences (JBIO) just delivered interim Phase 1 data suggesting an every-12-week dosing profile for JADE101 with ~70% IgA reductions. With $336M in cash, a recent $150M offering, and a market cap of roughly $1.44B, the stock offers a mid/long-term asymmetric payoff: buy near $22.71 with a stop at $18.50 and a pragmatic target of $34.00 over …
ATI is trading at premium multiples after a sustained rally driven by aerospace aftermarket strength and better aircraft production cadence. The company’s exposure to titanium, nickel-based alloys, and high-performance components gives it direct leverage to airframe build rates and defense modernization. We present a tactical long: enter at $220.00…
Hewlett Packard Enterprise has already rallied hard in 2026, but its record backlog, integrated networking push after the Juniper deal, and healthy FCF profile support another leg higher. Technicals are constructive and short interest remains material — a disciplined entry with a clear stop captures asymmetric upside while limiting risk.
Intuit's combination of tax market leadership and fast-moving AI integration creates a practical trade: buy INTU around $360 with a $420 target and a $335 stop. Strong free cash flow ($7.76B), high ROE (22%), and reasonable valuation (P/E ~21) support a long-term (180 trading days) position while the market digests legal noise and near-term tax sea…
TTM Technologies (TTMI) has become a core pick on the AI infrastructure trade. Q1 results showed revenue of $846M, up 30% year-over-year, and management raised guidance. The stock has pulled back from its 52-week high, creating a tactical long entry. I’m raising my target to reflect sustained AI-driven demand, a strategic European acquisition, and …
EyePoint plunged after a reported head-to-head miss of DURAVYU versus Eylea. The reaction looks outsized relative to the company's cash runway, the still-progressing clinical program, and heavy short positioning. We lay out a long trade with a strict stop and a long-term (46-180 trading days) horizon that targets recovery driven by trial nuance, sh…
